Kinnate Biopharma, Inc.  is a precision oncology company advancing a pipeline of therapeutics to treat patients with genomically defined vulnerabilities. Kinnate’s focus is on the design and development of selective small molecules with the mission to provide the right drug to the right patient. Headquartered in San Diego, CA, the Kinnate team comprises oncology experts, each with decades of experience developing small molecule therapies.

Foresite Capital has supported Kinnate since its Series A financing. Kinnate represents a prototypical Foresite Capital investment —  drug hunters focused on genetically-defined disease, addressing significant unmet medical need, with a team of top scientific advisors.


Kinnate was acquired by XOMA in February 2024.